EU/3/05/343

Table of contents

About

On 23 December 2005, orphan designation (EU/3/05/343) was granted by the European Commission to Eli Lilly Nederland B.V., The Netherlands, for enzastaurin hydrochloride for the treatment of glioma.

The sponsorship was transferred to Isabelle Ramirez, Germany, in February 2016.

The sponsorship was transferred to Dlrc Pharma Services Limited, Ireland, in October 2020.

Key facts

Active substance
Enzastaurin hydrochloride
Disease / condition
Treatment of glioma
Date of first decision
23/12/2005
Outcome
Positive
EU designation number
EU/3/05/343

Sponsor's contact details

Dlrc Pharma Services Limited
Chesterfield House
Clonmannon
Ashford A67 WR29
Co. Wicklow
Ireland
E-mail: regulatory.submissions@dlrc.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating